Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug zanidatamab aims to shrink early breast cancer tumors before surgery

NCT ID NCT05035836

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing a drug called zanidatamab in 20 people with early-stage, low-risk HER2-positive breast cancer. The drug is given intravenously, along with hormone therapy pills (letrozole or tamoxifen). The main goal is to see if the cancer disappears completely by the time of surgery. The study is currently recruiting at a single site.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
zanidatamab (also called ZW25), given intravenously, along with letrozole or tamoxifen pills
What this could lead to
If it works, this could point toward a new treatment option for early-stage HER2+ breast cancer that may reduce the need for chemotherapy.
What could go wrong
This is a very small, early-phase trial with only 20 participants and no comparison group. The drug may not work as hoped, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER HER2 POSITIVE

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • M D Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.